All Oncology News

The OncLive® News page includes the latest in clinical oncology news, including breaking regulatory decisions, clinical trial findings, pivotal and practice-changing data published in academic peer-reviewed journals, and more across solid and hematologic malignancies. Regulatory news includes new drug approvals by the FDA and European Union, priority review and breakthrough therapy designations, and orphan drug and fast track statuses.

World-Renowned Biochemist Joins Sylvester Comprehensive Cancer Center

July 17th 2023

One of the world’s foremost biochemists is joining Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine, bringing decades of groundbreaking research in genetics, epigenetics and cellular processes.

EMA Accepts Marketing Application for Zolbetuximab in CLDN18.2+ Gastric/GEJ Adenocarcinoma

July 17th 2023

The European Medicines Agency has accepted a marketing authorization application seeking the approval of zolbetuximab for first-line treatment of patients with Claudin18.2-positive, HER2-negative, unresectable, locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma.

FDA Accepts NDA for Rivoceranib Plus Camrelizumab in Unresectable HCC

July 17th 2023

The FDA has accepted for review a new drug application seeking the approval of rivoceranib in combination with camrelizumab as a first-line treatment option for patients with unresectable hepatocellular carcinoma.

DecisionDx-Melanoma 31-Gene Expression Profile Test Stratifies Patients With Cutaneous Melanoma

July 17th 2023

The DecisionDx-Melanoma 31-gene expression profile test displayed the capability to stratify patients with cutaneous melanoma by risk of death from the disease and receival of the 31-GEP test may result in a survival benefit compared with untested patients.

Prognostic Markers in Peripheral Blood Shine Light on Future Directions in NSCLC

July 16th 2023

Joseph Christopher Murray, MD, discusses the role of prognostic markers in non–small cell lung cancer and how data from the EMPOWER trials will guide future directions in the space.

ADCs and Radiotherapeutics Represent Novel Treatment Methods in RCC

July 15th 2023

The investigation of treatment regimens featuring antibody-drug conjugates or radiotherapeutics are part of the ongoing wave of research in renal cell carcinoma.

Lenvatinib/Pembrolizumab Benefit Is Upheld in Advanced RCC, Including ICI-Pretreated and Naïve Subgroups

July 14th 2023

The combination of lenvatinib and pembrolizumab continued to show clinical activity in patients with metastatic renal cell carcinoma, including in subsets of patients who had received or were naïve to checkpoint inhibitors.

Tumor Sequencing Identifies Host Signatures Tied to Immunotherapy Response in Advanced RCC

July 14th 2023

Higher levels of baseline TCR clonality in peripheral blood mononuclear cells (PBMCs) and baseline IgG1 fraction in PBMCs and tumor tissue were identified in an institutional cohort of samples from patient with metastatic renal cell carcinoma.

Olaparib Monotherapy Showcases Antitumor Activity in BAP1-mutated RCC

July 14th 2023

Olaparib monotherapy elicited responses with favorable tolerability in patients with renal cell carcinoma whose tumors harbored BAP1 or other DNA repair gene mutations, according to data from the interim analysis of the phase 2 ORCHID trial presented during the 2023 Kidney Cancer Research Summit.

Knowledge Gap Remains for Sequencing of Later-Line Treatments of Advanced RCC

July 14th 2023

Although the use of immunotherapy treatment approaches continues to become more prevalent in advanced renal cell carcinoma, high-level evidence showing benefit of sequential administration of these agents are limited.

Leveraging Biology to Guide First-Line Treatment of Clear Cell RCC

July 14th 2023

Determining the appropriate front-line treatment pathway for patients with clear cell renal cell carcinoma may not always align with risk stratification features.

Frontline Immunotherapy, Delayed Nephrectomy May Allow for Improved Disease Control in mRCC

July 14th 2023

Neoadjuvant immunotherapy–based combinations led to reductions in tumor size and pathologic necrosis at the time of cytoreductive nephrectomy in patients with metastatic renal cell carcinoma.

Adjuvant Pembrolizumab Provides Survival Benefit Across ccRCC Risk Groups and Disease Stages

July 14th 2023

Adjuvant pembrolizumab prolonged disease-free survival and distant metastasis-free survival compared with placebo across The University of California Los Angeles Integrated Staging System–categorized subgroups of patients with clear cell renal cell carcinoma.

Frontline Lenvatinib Plus Pembrolizumab Produces Superior Responses Vs Sunitinib in Advanced RCC

July 14th 2023

Lenvatinib plus pembrolizumab demonstrated improved overall response rates compared with sunitinib monotherapy in treatment-naïve patients with advanced renal cell carcinoma regardless of risk status or PD-L1 expression.

Sylvester Cancer Researcher Honored with ASCO Early Career Award

July 14th 2023

Shria Kumar, MD, a colorectal cancer researcher with Sylvester Comprehensive Cancer Center, part of the University of Miami Miller School of Medicine, has been awarded a Conquer Cancer Career Development Award from the American Society of Clinical Oncology.

FLX475 Alters TME to Enhance Anti–PD-1/PD-L1 Response in NK/T-cell Lymphoma

July 13th 2023

Single-agent treatment with the novel CCR4 antagonist FLX475 led to changes in the tumor microenvironment to a phenotype more associated with responses to anti–PD-1/PD-L1 therapy in patients with natural killer/T-cell lymphoma.

Key Trials at ASCO 2023 Highlight Role of Perioperative Treatment Approaches in NSCLC

July 13th 2023

Jarushka Naidoo, MBBCh, discussed the clinical significance of datasets from several phase 3 trials presented at the 2023 ASCO Annual Meeting, including ADAURA, KEYNOTE-617, CheckMate 816, and CheckMate 9LA trials.

Despite Diagnostic Challenges, ADCs Are Poised to Expand Treatment Options in Lung Cancer

July 13th 2023

As antibody-drug conjugates become an established part of the lung cancer treatment paradigm, identifying which patients will benefit the most from treatment with these highly specific agents remains a challenge for clinicians.

First-line Enfortumab Vedotin Plus Pembrolizumab Has Durable Activity in Urothelial Carcinoma

July 13th 2023

Responses achieved with enfortumab vedotin plus pembrolizumab were found to be rapid and durable in patients with previously untreated locally advanced or metastatic urothelial carcinoma who were cisplatin ineligible.

PROSPECT Trial Looks to Add Effective Option for Patients With R/R PCNSL

July 13th 2023

Efforts to develop the first FDA-approved agent specifically for patients with primary central nervous system lymphoma have been initiated with the phase 2 PROSPECT trial.